OPKO Health, Inc. is a multinational healthcare company involved in both diagnostics and pharmaceuticals, with operations in the United States and several countries, including Ireland, Chile, Spain, Israel, and Mexico. Its Diagnostics segment includes BioReference Laboratories, which provides a range of laboratory testing services and core genetic testing, such as the 4Kscore prostate cancer test. The Pharmaceuticals segment offers products like Rayaldee, aimed at treating secondary hyperparathyroidism and vitamin D insufficiency in chronic kidney disease patients, and is developing various drugs for conditions including type 2 diabetes, obesity, and hemophilia. OPKO also focuses on creating specialty active pharmaceutical ingredients and has a portfolio that includes nutraceuticals, veterinary products, and generics. The company is committed to leveraging its expertise in discovery, development, and commercialization to explore growth opportunities and expand its geographical presence. Incorporated in 1991 and headquartered in Miami, Florida, OPKO Health continues to pursue innovations in medical treatments and diagnostics.
HealthSnap, Inc. is a healthcare technology company that focuses on processing and managing lifestyle data for patients. The company's primary product, the Electronic Lifestyle Record, serves as a lifestyle assessment platform, enabling healthcare providers to standardize the collection, interpretation, and tracking of patient lifestyle health data. This integration helps prevent chronic diseases by making personalized health data accessible and actionable for individuals. Additionally, HealthSnap offers a remote patient monitoring platform designed for virtual chronic disease management, allowing healthcare organizations to enhance patient outcomes, decrease readmissions, and reduce overall care costs. Founded in 2015, HealthSnap is headquartered in Miami, Florida, and also has a location in San Mateo, California.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.
Phio Pharmaceuticals Corp. is a biotechnology company specializing in the development of next-generation immuno-oncology therapeutics in the United States. The company utilizes its self-delivering RNAi (sd-rxRNA) therapeutic platform to create compounds aimed at enhancing the efficacy of cancer treatments. Its lead candidates include PH-762, which targets the PD-1 checkpoint protein on immune cells; PH-804, which targets the suppressive receptor TIGIT; and PH-790, which focuses on the PD-L1 protein that inhibits immune attacks on nonharmful cells. These compounds are designed for use in adoptive cell transfer and immunotherapy applications. Phio Pharmaceuticals collaborates with several research institutions, including Gustave Roussy and Medigene AG, to advance its therapeutic innovations. Established in 2011 and headquartered in Marlborough, Massachusetts, the company was previously known as RXi Pharmaceuticals Corporation, a name it changed in November 2018.
VBI Vaccines Inc. is a biopharmaceutical company focused on developing vaccines for infectious diseases and immuno-oncology, with operations in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine suitable for various age groups, and is advancing VBI-2601, an immunotherapeutic candidate aimed at achieving a functional cure for chronic hepatitis B. Utilizing its enveloped virus-like particle (eVLP) platform technology, VBI develops vaccines that closely mimic target viruses to elicit strong immune responses. Key candidates in its eVLP program include VBI-1901, a glioblastoma vaccine in Phase I/IIa clinical trials, and VBI-1501, a cytomegalovirus vaccine that has completed Phase I trials. VBI Vaccines also engages in collaboration and licensing agreements with various pharmaceutical and biotechnology entities, including partnerships for the commercialization of its hepatitis B vaccine and the development of a pan-coronavirus vaccine candidate. Headquartered in Cambridge, Massachusetts, the company also has research facilities in Ottawa, Canada.
Transition Therapeutics Inc. is a biopharmaceutical company based in Toronto, Canada, focused on researching and developing therapeutic agents for various disease indications. The company's lead product, ELND005, is aimed at treating agitation and aggression associated with Alzheimer's disease and has completed a Phase II/III clinical trial. Transition is also advancing TT401, a drug candidate currently in Phase II clinical trials for the treatment of type 2 diabetes and obesity, under a collaboration with Eli Lilly. Additionally, the company is developing TT701, a selective androgen receptor modulator targeting androgen deficiencies. Transition Therapeutics, founded in 1987, has evolved its pipeline to include both externally acquired and internally developed preclinical drug candidates.
Arno Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative treatments for cancer and other life-threatening diseases. The company's pipeline features several drug candidates, including Onapristone, a type 1 anti-progestin hormone blocker currently in Phase I/II clinical studies aimed at treating various solid tumors, including breast and endometrial cancers in post-menopausal women, as well as advanced castration-resistant prostate cancer in men. Another candidate, AR-12, has completed Phase I clinical studies for the treatment of solid tumors and hematological malignancies, and is also undergoing pre-clinical studies for various anti-microbial targets. Additionally, AR-42, an orally available therapy, is in Phase I investigator-initiated clinical studies for hematological malignancies and solid tumors. Arno Therapeutics has established license agreements with multiple institutions and a co-development agreement with Leica Biosystems Newcastle Ltd., and is headquartered in Flemington, New Jersey.
BioReference is the third largest full service clinical diagnostic laboratory in the U.S. providing testing and related services to physician offices, clinics, hospitals, long term care facilities, employers, governmental units and correctional institutions. We offer a comprehensive test list focusing on molecular diagnostics, anatomical pathology, genetics, and women’s health. Moreover, through its GeneDx subsidiary, BioReference has an international presence in more than 50 countries around the world.
EirGen Pharma Ltd. is a pharmaceutical company based in Waterford, Ireland, specializing in the development, registration, and commercial manufacture of high potency solid dosage forms. Established in 2004, the company operates a state-of-the-art facility designed for the production of oncology, cytotoxic, steroidal, and immunosuppressant products, ensuring compliance with stringent safety standards. EirGen Pharma provides a range of services, including clinical trial management, drug formulation development, and contract manufacturing, catering to both human and veterinary markets. The company is fully licensed to manufacture and package investigational medicinal products and offers a variety of dosage forms such as film-coated tablets, soft-gel capsules, and powder or liquid-filled hard shells. EirGen Pharma serves clients across multiple regions, including the United States, Europe, Japan, Canada, Australia, the Middle East, and Africa. As of May 2015, it operates as a subsidiary of OPKO Ireland Limited.
Inspiro Medical Ltd. is a medical device company dedicated to the development of a global inhalation platform designed to deliver both small molecules such as corticosteroids or beta agonists; and macromolecules such as antibodies or vaccines. The Company is currently performing clinical trials with asthmatic children using Inspiromatic, its proprietary dry powder inhaler.
PROLOR Biotech is developing proprietary versions of already-approved therapeutic proteins. The Company’s Carboxyl Terminal Peptide technology can be attached to an array of existing therapeutic proteins, stabilizing the therapy in the bloodstream and extending its lifespan without additional toxicity or loss of desired biological activity. PROLOR products under development include Human Growth Hormone (“hGH”) for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone (a $3 billion market opportunity). PROLOR’s hGH could potentially be injected once a week or twice per month instead of daily. PROLOR’s hGH is scheduled for Phase III trials in 2013.
Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.
Claros Diagnostics, Inc. is creating products to move in-vitro medical diagnostic tests out of the laboratory and into the hands of physicians and patients.
Fabrus LLC was founded in 2007 as the first company in The Pfizer Incubator. The company has assembled a seasoned scientific team that has met and exceeded its milestones by establishing a unique antibody discovery platform and discovering multiple preclinical lead candidates against important cancer targets.
Vidus Ocular
Acquisition in 2008
Vidus Ocular, Inc. develops an implantable physiologic device that is designed to address the shortcomings of glaucoma treatments. It offers Aquashunt, which is a shunt to treat glaucoma, the cause of blindness in the United States. The company is based in the United States. As of May 7, 2008, Vidus Ocular, Inc. operates as a subsidiary of Opko Health, Inc.
Acuity Pharmaceuticals is a pharmaceutical company based in Philadelphia, Pennsylvania, established in 2007. It specializes in the treatment and prevention of ophthalmic diseases, particularly focusing on age-related macular degeneration (AMD) and diabetic retinopathy (DR). The company is developing small interfering RNA compounds aimed at addressing vision loss associated with these conditions. One of its key products, Cand5, is a clinical compound designed to inhibit vascular endothelial growth factor, thereby targeting adult vision loss. In June 2011, Acuity Pharmaceuticals was acquired by OPKO Health, enhancing its capabilities in the ophthalmic market.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.